Fulcrum Therapeutics (NASDAQ: FULC) Stock Plunges Amid Drug Discontinuation and Downgrade

Font: Financial Modeling Prep  • Jun 02, 2026

• Drug Program Halted: Fulcrum Therapeutics discontinued its sickle cell disease drug, pociredir, due to U.S. FDA concerns over cancer risks.
• Significant Market Reaction: Citigroup downgraded the stock to Underweight, leading to a more than 50% drop in share price and substantial market volatility.
• Strategic Review & Investigation: The company is now exploring strategic options, including a potential sale or merger, while also facing an investigation into compliance with federal securities laws.

Fulcrum Therapeutics (NASDAQ: FULC) is a leading biotechnology company. It focuses on creating innovative treatments for rare diseases that are caused by genetic problems. The company's work involves developing new drug therapies to address the root causes of these serious conditions, aiming to improve patient outcomes.

On June 2, 2026, the investment bank Citigroup (NYSE: C) downgraded Fulcrum Therapeutics stock. The stock rating changed from Underperform to Underweight, suggesting a more negative outlook for the biotech stock. At the time of this announcement, the stock price was $3.14.

This stock downgrade follows major news from Fulcrum Therapeutics. The company is stopping the development of its main drug candidate for sickle cell disease, called pociredir. This critical decision was made after the U.S. Food and Drug Administration (FDA) raised significant concerns about potential cancer risks associated with the drug, as highlighted by Reuters.

The market reacted strongly to this development. Shares of Fulcrum Therapeutics fell 50% in premarket trading. The stock price dropped by $3.28, or 51.09%, during the day. Fulcrum Therapeutics stock has traded between a low of $2.83 and a high of $3.26 during the session, reflecting significant market volatility.

Following the discontinuation of its key drug program, Fulcrum Therapeutics is actively reviewing its strategic options. This critical review could potentially lead to a sale or merger of the company. Additionally, the law firm Holzer & Holzer, LLC is investigating whether Fulcrum Therapeutics complied with federal securities laws, adding another layer of complexity to the situation.